Načítá se...
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Liposomal irinotecan (nal-IRI; Onivyde(®); also known as pegylated liposomal irinotecan) has been developed with the aim of maximising anti-tumour efficacy while minimising drug-related toxicities compared with the conventional (non-liposomal) formulation of this topoisomerase 1 inhibitor. In combin...
Uloženo v:
| Vydáno v: | Drugs |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7347682/ https://ncbi.nlm.nih.gov/pubmed/32557396 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01336-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|